Keros Therapeutics (KROS) Assets (2019 - 2026)

Keros Therapeutics (KROS) has reported Assets for 8 consecutive years, with $287.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 62.02% year-over-year to $287.6 million; the trailing twelve-month figure through Jun 2026 stood at $287.6 million (down 62.02% YoY), and the FY2025 full-year result was $338.0 million, down 45.12% from the prior year.
• Assets slipped to $287.6 million in Q2 2026 per KROS's latest filing, from $338.0 million in the prior quarter.
• Across five years, Assets topped out at $784.6 million in Q1 2025 and bottomed at $226.7 million in Q2 2022.
• Historically, Assets has averaged $441.4 million across 5 years, with a median of $370.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Assets soared 77.56% in 2024, then slumped 62.02% in 2026.
• Over 5 years, Assets stood at $306.8 million in 2022, then grew by 20.62% to $370.0 million in 2023, then soared by 66.44% to $615.9 million in 2024, then tumbled by 45.12% to $338.0 million in 2025, then declined by 14.92% to $287.6 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $287.6 million, $338.0 million, and $742.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.